Clinical Trials Logo

Essential Hypertension clinical trials

View clinical trials related to Essential Hypertension.

Filter by:

NCT ID: NCT02822222 Completed - Clinical trials for Essential Hypertension

Safety Study of RMJH-111b to Treat Essential Hypertension

Start date: June 10, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study was to evaluate the safety of RMJH-111b, including how well it is tolerated, and the effect of RMJH-111b on blood pressure in subjects with hypertension. The study also measured the amount of magnesium in the blood and urine before and after RMJH-111b administration to evaluate what the body does to RMJH-111b (pharmacokinetics).

NCT ID: NCT02738632 Completed - Clinical trials for Essential Hypertension

Efficacy and Safety of TAH Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients

Start date: May 2015
Phase: Phase 3
Study type: Interventional

Randomized, Double-Blind, Multi-Center, Phase 3 Trial to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Hydrochlorothiazide Combination in Comparison with Telmisartan/Amlodipine Combination for Essential Hypertension Patients not Controlled by Telmisartan/Amlodipine Combination

NCT ID: NCT02722265 Completed - Clinical trials for Essential Hypertension

Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension

Start date: March 2016
Phase: Phase 3
Study type: Interventional

To examine antihypertensive effect, pharmacodynamics, and safety of long-term administration of CS-3150 as monotherapy and in combination with calcium channel blocker or renin-angiotensin system inhibitor in patients with essential hypertension.

NCT ID: NCT02687178 Completed - Clinical trials for Essential Hypertension

Canrenone as Add-on in Patients With Essential Hypertension

Start date: October 2010
Phase: Phase 4
Study type: Interventional

To evaluate the efficacy on blood pressure reduction, safety and tolerability of two different dosages of canrenone as add-on therapy in patients already treated with Angiotensin Converting-Enzyme Inhibitors (ACE-I) or Angiotensin II Receptor Blockers (ARBs) and diuretics at the maximum dosage.

NCT ID: NCT02612298 Completed - Clinical trials for Essential Hypertension

Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate

ESAHOM
Start date: August 2015
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the efficacy and safety of Arotinolol Hydrochloride and Metoprolol succinate on morning blood pressure, heart rate and target organ damage in patients with essential hypertension. To provide evidence for hypertension treatment. A group: Arotinolol Hydrochloride, oral, 5-15mg, bid for 12 weeks. B group: Metoprolol succinate sustained-release tablet, oral, 23.75-71.25mg, qd for 12 weeks.

NCT ID: NCT02603809 Completed - Clinical trials for Essential Hypertension

Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension

Start date: December 14, 2015
Phase: Phase 2
Study type: Interventional

The main objective will be to evaluate the dose-response of ACT-132577 (aprocitentan) on diastolic blood pressure (DBP) in participants with grade 1 or 2 essential hypertension. Secondary objectives will be to evaluate the dose-response of ACT-132577 on: systolic blood pressure (SBP); control and response rate of blood pressure; 24-hour ambulatory blood pressure monitoring (ABPM) and to evaluate the safety and tolerability of a once daily oral regimen of 4 doses of ACT-132577.

NCT ID: NCT02579356 Completed - Clinical trials for Essential Hypertension

To Evaluate the Drug-drug Interaction Between Telmisartan and Atorvastatin in Healthy Male Volunteers

Start date: May 2014
Phase: Phase 1
Study type: Interventional

The study design was composed of 2 parts, 2-way crossover and multiple-dose. There are having 2 groups in each part that have divided period 1 and period 2, and wash-out period is 16 days between periods. Each group is taking Telmisartan (80mg) and/or Atorvastatin (80mg) once a day for 6 days.

NCT ID: NCT02553512 Completed - Clinical trials for Essential Hypertension

Helius in Hypertension-I: The UK Hypertension Registry

Start date: September 2013
Phase: N/A
Study type: Observational [Patient Registry]

The purpose of this study is to demonstrate the use of a digital health offering in the management of persistent hypertension during chronic anti-hypertensive treatment.

NCT ID: NCT02517866 Completed - Clinical trials for Type 2 Diabetes Mellitus

Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia

Start date: July 13, 2015
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil (AZM) in Asian adult participants with both essential hypertension and type 2 diabetes.

NCT ID: NCT02495324 Completed - Clinical trials for Essential,Hypertension

Fimasartan Achieving SBP Target (FAST) Study

FAST
Start date: June 2015
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Fimasartan compared to Valsartan and Olmesartan(reference group) in patients with mild to moderate essential hypertension. Patients have 2 weeks of placebo run-in and wash out period, 2 weeks of taking required dose and 4 weeks of taking double dose.